Evidence map›Paper›PMID 37858962›Full record

ReviewBritish journal of haematology2023

Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?

Hosuk Ryou, Oliver Lomas, Helen Theissen, Emily Thomas, Jens Rittscher, Daniel Royston

Open access · hybridAbstract readReview
In one paragraph

Review in British journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hosuk RyouNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Oliver LomasDepartment of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID 0000-0003-4121-6468
Helen TheissenDepartment of Engineering Science, Institute of Biomedical Engineering (IBME), University of Oxford, Oxford, UK.
Emily ThomasDepartment of Engineering Science, Institute of Biomedical Engineering (IBME), University of Oxford, Oxford, UK.
Jens RittscherDepartment of Engineering Science, Institute of Biomedical Engineering (IBME), University of Oxford, Oxford, UK.
Daniel RoystonNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-5151-2378
University of Oxford · GBOxford University Hospitals NHS Trust · GBTransport Research Laboratory (United Kingdom) · GB

Funding

Cancer Research UK 30721
6 · The paper itself

Abstract

The diagnosis of myeloproliferative neoplasms (MPN) requires the integration of clinical, morphological, genetic and immunophenotypic findings. Recently, there has been a transformation in our understanding of the cellular and molecular mechanisms underlying disease initiation and progression in MPN. This has been accompanied by the widespread application of high-resolution quantitative molecular techniques. By contrast, microscopic interpretation of bone marrow biopsies by haematologists/haematopathologists remains subjective and qualitative. However, advances in tissue image analysis and artificial intelligence (AI) promise to transform haematopathology. Pioneering studies in bone marrow image analysis offer to refine our understanding of the boundaries between reactive samples and MPN subtypes and better capture the morphological correlates of high-risk disease. They also demonstrate potential to improve the evaluation of current and novel therapeutics for MPN and other blood cancers. With increased therapeutic targeting of diverse molecular, cellular and extra-cellular components of the marrow, these approaches can address the unmet need for improved objective and quantitative measures of disease modification in the context of clinical trials. This review focuses on the state-of-the-art in image analysis/AI of bone marrow tissue, with an emphasis on its potential to complement and inform future clinical studies and research in MPN.

Indexed as

Hematologic NeoplasmsMyeloproliferative DisordersArtificial IntelligenceBiopsyBone MarrowHumansartificial intelligencebone marrow biopsyclinical trialsmarrow fibrosismegakaryocytesmyeloproliferative neoplasm

Identifiers

PMID37858962
PMCPMC10952168
OpenAlexW4387798896

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.